Eli Lilly to Acquire Kelonia Therapeutics in Deal Worth Up to $7B to Boost Cancer Pipeline
- 17 hours ago
- 1 min read
San Diego, CA, April 19, 2026 (Reuters) -- Eli Lilly has agreed to acquire Kelonia Therapeutics in a transaction valued at up to $7 billion. The deal includes an upfront payment along with additional milestone-based considerations tied to development progress. The acquisition is intended to strengthen Lilly’s oncology portfolio with next-generation cancer therapies.
Read full article here.